Cleveland Research initiated coverage of Lam Research (LRCX) with a Neutral rating. The firm’s checks suggest slower than expected revenue recovery due to end demand concerns, new fab construction being on hold, and U.S. CHIPS Act funding delays, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LRCX:
- Lam Research price target lowered to $87 from $90 at Citi
- Lam Research price target raised to $78 from $76 at Morgan Stanley
- Lam Research issues statement on newly announced export regulations
- Early notable gainers among liquid option names on December 2nd
- U.S. Enacts Toughest Chip Export Controls to Curb China’s AI Ambitions